XtremeVRI AG

XtremeVRI AG
XtremeVRI develops a software called Alterniity designed to detect early signs of Alzheimer’s and dementia, and to retard the onset and progression of the disease.
Social Purpose: 
According to the new estimates on the number of people with dementia, there is an increase of 17% on the figures published in 2009, with data showing that the number of people with dementia will increase from 115 to 135 million by 2050. Dementia due to Alzheimer's disease (AD) is preceded by about 5 to 6 years of accelerated decline of multiple cognitive functions. The traditional system of “informal” care by family, friends, and community alone will not be sustainable as the number of dependent older people will treble by 2050. In most low and middle income countries, this figure is set to quadruple. As the number of older persons suffering from dementia is already large, and is expected to grow in the future, dementia has become a health policy priority in many countries due to exponentially increment of caregiving cost. Future aims for the national policies will typically involve: low-cost techniques to reliable diagnose the risk of dementia at the earliest possible stage (early biomarkers research), prevent the cognitive decline by means of non-pharmacological interventions and promote the healthy aging process by planning skills that help the seniors cope with everyday activities and make them almost independent.
Social Impact: 
The aim of this project is to facilitate adequate evidence generation, both at the stage of the initial development of the technology and after an early assessment has been done at time of the introduction of the technology to healthcare. Identifying, evaluating and monitoring the diffusion of emerging/new technologies are activities of growing importance. For this project we will design a randomized, single-blind clinical trial and report it with the Health Technology Assessment (HTA) Core Model which covers scientific, medical, social, economic, and ethical issues.
Innovative Character: 
Recently, our group produced very promising results on the value of a Virtual Reality psychomotor and cognitive stimulation environment for complex everyday activities assessment, which was evaluated as an early biomarker, compared to the established biomarkers, such as brain-scanning of event related potentials (ERPs), magnetic resonance imaging (MRI) or neuropsychological tests regarding it’s predictive value in patients at risk of developing AD in the near future (Tarnanas et al, 2014). In addition to early screening, VR has also proven beneficial as a form of brain training for the rehabilitation of the cognitive decline at the very early stages of dementia. In conclusion, the “potential for change” of this project is to develop a novel tool that will provide therapists with an innovative means of dealing with cognitive rehabilitation and offer patients customized rehabilitation sessions, on the basis of simulated iADL. Tarnanas, I., Tsolaki, M., Nef, T., Muri, R., & Mosimann, U. P. (2014). Can a novel computerized cognitive screening test provide additional information for early detection of Alzheimer Disease? Alzheimer’s & Dementia : The Journal of the Alzheimer's Association.